Last reviewed: May 2026 — Dr. Bismah Irfan, MD
As of May 2026, retatrutide is not yet FDA-approved. Eli Lilly’s investigational triple-agonist remains in Phase 3 clinical trials (the TRIUMPH program), with the earliest plausible New Drug Application filing in Q4 2026 and a potential FDA decision in 2027 or 2028. It is not legally available for prescription use in the United States outside of an active clinical trial.
If you searched “is retatrutide FDA approved” hoping to find it at your pharmacy, the short answer is: not yet, and not in 2026. Below is a current snapshot of where retatrutide stands — what the drug is, what the Phase 3 data look like, when approval is realistically expected, and what your safe options are right now.
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational, once-weekly injectable peptide developed by Eli Lilly. Unlike semaglutide (Ozempic/Wegovy), which activates a single receptor (GLP-1), or tirzepatide (Mounjaro/Zepbound), which activates two (GLP-1 + GIP), retatrutide activates three metabolic receptors at once:
- GLP-1 — slows gastric emptying, suppresses appetite, improves insulin response
- GIP — additional insulin-sensitivity and appetite effects
- Glucagon — boosts energy expenditure and lipolysis (this is the new mechanism)
The glucagon component is what makes retatrutide unique. By layering metabolic-rate stimulation on top of appetite suppression, the drug has produced the largest weight-loss numbers seen in any GLP-class trial to date.
Phase 3 Status: TRIUMPH Program (May 2026 Snapshot)
The TRIUMPH program is the set of large Phase 3 trials that will form the core of Eli Lilly’s eventual FDA submission. Where each readout stands as of this writing:
| Trial | Population | Status (May 2026) | Headline result |
|---|---|---|---|
| TRIUMPH-4 | Adults with obesity, no diabetes | Completed Dec 2025 | ~28.7% mean weight loss at the top dose at 76 weeks |
| TRIUMPH-1 | Adults with obesity | Readout expected Q2-Q3 2026 | Pending |
| TRIUMPH-2 | Obesity + cardiovascular risk | Readout expected Q2-Q3 2026 | Pending |
| TRIUMPH-3 and others | Type 2 diabetes, NAFLD, additional indications | Ongoing through 2026 | Pending |
For context: semaglutide (Wegovy) produced about 15% weight loss in its pivotal STEP trial; tirzepatide (Zepbound) about 21% in SURMOUNT-1. The TRIUMPH-4 readout of ~28.7% places retatrutide on track to become the most effective GLP-class weight-loss drug yet — if the remaining trials replicate the result and the safety profile holds.
When Will Retatrutide Be FDA Approved?
The realistic timeline, based on the current trial schedule:
- Q2-Q3 2026 — TRIUMPH-1 and TRIUMPH-2 primary readouts. These two, combined with the already-reported TRIUMPH-4 data, give Lilly the efficacy package needed for an obesity-indication submission.
- Q4 2026 (earliest) — New Drug Application (NDA) filing with the FDA. This is the earliest plausible window and assumes no regulatory pre-submission delays.
- 2027 (mid-to-late) — earliest possible FDA approval decision, assuming a standard 10-month priority review. A full standard review pushes the decision into 2028.
Two important caveats. First, the FDA has not granted retatrutide Breakthrough Therapy designation as of May 2026, which means there is no built-in mechanism for an accelerated review. Second, the FDA’s questions about new GLP-class drugs have grown more detailed since 2024 — pancreatitis surveillance, thyroid C-cell signals, and gastroparesis monitoring all add review time. Bottom line: expect 2027 at the earliest, 2028 more likely.
Is Retatrutide Legal to Use Now?
Outside of a clinical trial, no. Retatrutide is not on the FDA’s list of approved drugs and is not on the FDA’s Drug Shortage list (which is what enabled compounded semaglutide and tirzepatide during the 2023-2025 shortages). That distinction matters legally:
- 503A and 503B compounding pharmacies are not permitted to compound retatrutide for human use. Any U.S. pharmacy advertising compounded retatrutide is operating outside FDA boundaries.
- “Research-only” or “not for human use” peptide sellers are not regulated as drug manufacturers. The vials are not subject to FDA purity, sterility, or potency standards. Using them is unsafe and not lawful for personal medical use.
- Clinical trial enrollment is the only legal way to receive retatrutide in the U.S. right now. ClinicalTrials.gov lists active TRIUMPH sites; eligibility is narrow and most arms are now fully enrolled.
Safety Signals to Watch in the Trial Data
The glucagon-receptor activation that drives retatrutide’s strong weight-loss numbers is also its main source of regulatory uncertainty. From the published Phase 2 and the TRIUMPH-4 topline, the side-effect profile that the FDA will scrutinize:
- Heart rate — a sustained 4-7 beat-per-minute increase at the highest doses. The FDA will want long-term cardiovascular outcome context.
- Nausea, vomiting, diarrhea — common to the GLP class, dose-dependent, generally manageable with slow titration.
- Glucose excursions — the glucagon component can raise fasting glucose in some patients without diabetes. Monitoring matters.
- Injection-site reactions — low single-digit incidence, mostly mild.
None of these are flagged as deal-breakers, but each will get its own FDA review section, and any of them could prompt a Risk Evaluation and Mitigation Strategy (REMS) requirement at approval.
What Are Your Options Right Now (May 2026)?
If your goal is medical weight loss now, three FDA-approved options exist today:
- Semaglutide (Wegovy, Ozempic) — approved for obesity (Wegovy) and type 2 diabetes (Ozempic). Standard dosing schedule here.
- Tirzepatide (Zepbound, Mounjaro) — approved for obesity (Zepbound) and type 2 diabetes (Mounjaro). Stronger weight-loss data than semaglutide.
- Liraglutide (Saxenda) — older GLP-1, daily injection, modest weight loss, lower cost.
A medically-supervised program with one of these approved drugs will deliver meaningful weight loss right now without any of the legal or sourcing risks attached to investigational retatrutide. At iVitality MD in Houston, Dr. Bismah Irfan reviews medical history, screens for contraindications, and prescribes the GLP-class drug best matched to each patient’s profile.
Frequently Asked Questions
Is retatrutide FDA approved in 2026?
No. As of May 2026, retatrutide is in Phase 3 trials. The earliest plausible FDA approval is 2027.
Can I get a prescription for retatrutide?
No legitimate U.S. prescription exists outside of a clinical trial. Any provider or pharmacy offering retatrutide commercially is operating outside FDA boundaries.
How is retatrutide different from Ozempic and Mounjaro?
Retatrutide activates three metabolic receptors (GLP-1, GIP, glucagon) versus one for semaglutide and two for tirzepatide. The third receptor — glucagon — boosts energy expenditure, which appears to drive the larger weight-loss numbers in Phase 3.
How much weight does retatrutide cause?
TRIUMPH-4, the first Phase 3 obesity readout (Dec 2025), reported about 28.7% mean weight loss at the top dose at 76 weeks — the largest figure seen in any GLP-class trial so far.
What about compounded retatrutide?
Compounding retatrutide for human use is not permitted by the FDA. The drug is not on the FDA Drug Shortage list (which is what authorized compounded semaglutide and tirzepatide during the 2023-2025 shortages).
Where can I find updates?
ClinicalTrials.gov for trial status (search “retatrutide”), Eli Lilly’s investor relations page for readout announcements, and the FDA’s Drugs@FDA database for the eventual approval. We update this page after every major Phase 3 readout.
This article is for educational purposes only and is not medical advice. For a personalized consultation about FDA-approved weight-loss medications, contact iVitality MD in Houston.